HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) General Information

Description

Pipeline of novel preclinical-stage AT2R agonists of a company based in Uppsala, Sweden.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Uppsala
  • Sweden
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Corporate Office
  • Uppsala
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists)‘s full profile, request access.

Request a free trial

HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) FAQs

  • Where is HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) headquartered?

    HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) is headquartered in Uppsala, Sweden.

  • What industry is HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) in?

    HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists)’s primary industry is Buildings and Property.

  • Is HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) a private or public company?

    HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) is a Private company.

  • What is the current valuation of HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists)?

    The current valuation of HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) is .

  • What is HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists)’s current revenue?

    The current revenue for HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) is .

  • When was HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) acquired?

    HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) was acquired on 02-Nov-2020.

  • Who acquired HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists)?

    HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) was acquired by Vicore Pharma Holding.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process